Summary & Overview
HCPCS J2405: Injection, Ondansetron Hydrochloride, per 1 mg
HCPCS Level II code J2405 denotes the injectable form of ondansetron hydrochloride billed per 1 mg. Ondansetron is a commonly used antiemetic across acute care, oncology, and perioperative settings; accurate coding for injectable ondansetron is important for clinical documentation, reimbursement consistency, and pharmacy-administration workflows nationwide. This analysis covers major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise explanation of the clinical context for J2405, typical sites of service, and the implications for billing and claims processing. The publication includes benchmarked reimbursement ranges and payer-specific guidance where available, review of common billing modifiers and claim scenarios, and a summary of policy updates that affect injectable medication billing. The content also highlights operational considerations for infusion suites and emergency departments that frequently administer parenteral antiemetics.
Data not available in the input will be noted where applicable. The goal is to provide operational and policy-oriented reference material to aid coding teams, revenue cycle professionals, and clinical administrators who manage parenteral ondansetron billing nationally.
Billing Code Overview
HCPCS Level II code J2405 describes an injection of ondansetron hydrochloride, billed per 1 mg. This code represents administration of the antiemetic medication ondansetron in injectable form.
-
Service type: Injectable medication administration (single-agent, per mg billing)
-
Typical site of service: Administered in outpatient infusion centers, hospital inpatient and outpatient settings, emergency departments, oncology clinics, and other ambulatory care locations where parenteral antiemetic therapy is given.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old female undergoing outpatient chemotherapy for metastatic breast cancer presents to the oncology infusion suite with a history of severe nausea and vomiting related to her cisplatin-based regimen. The oncology nurse verifies orders and prepares an intravenous antiemetic. The medication administered is ondansetron hydrochloride by IV push or infusion, dosed per milligram using HCPCS Level II code J2405 (injection, ondansetron hydrochloride, per 1 mg). The nurse documents indication, dose, route, lot number, and site of administration in the electronic health record and records the associated ICD-10 diagnosis for chemotherapy-induced nausea and vomiting.
The clinical workflow includes medication reconciliation and allergy check, confirmation of IV access, verification of the provider order and patient identity, preparation of ondansetron per institutional policy, administration by a licensed clinician, monitoring for immediate adverse effects (e.g., QT prolongation symptoms, headache, constipation), and documentation of response to therapy. Billing staff link the administered milligrams to J2405 units and append an appropriate modifier if necessary (for example, a modifier indicating distinct procedural service or medically necessary service level).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |